Hyderabad-based pharmaceutical company Laurus Labs on Thursday, October 29, reported consolidated net profit of Rs 441 crore for the September quarter (Q2 FY27), a surge of 126 per cent from Rs 195 crore in the same quarter last year. Revenue climbed 33 per cent year-on-year to Rs 2,206 crore, from Rs 1,653 crore a year earlier.
Source: Mirror Now
The growth was led by the company's contract development and manufacturing (CDMO) business, where revenue rose 75 per cent to Rs 904 crore on commercial supplies, progress in late-stage clinical projects and the ramp-up of new production assets. Within CDMO, small molecules grew 86 per cent, while the bio business fell 38 per cent due to campaign phasing, Mirror Now reported.
Source: Mirror Now
The affordable medicines division grew 15 per cent to Rs 1,302 crore, supported by steady order volumes and pricing resilience in the ARV and US portfolios. Finished dosage forms (FDF) revenue rose 31 per cent to Rs 677 crore, while API revenue was largely stable at Rs 625 crore.
Source: Mirror Now
The board, which met on October 29 to approve the unaudited results for the quarter and half-year ended September 30, 2026, declared an interim dividend of Re 1 per share for FY27, with the record date fixed as November 6, according to the company's exchange filing reported by Upstox. Consolidated total income for the quarter was Rs 2,219.38 crore, against Rs 1,680.43 crore a year earlier, and basic earnings per share rose to Rs 8.17 from Rs 3.61, Kalkine reported from the filing.
Source: Upstox
Founder and CEO Satyanarayana Chava described the quarter as a record-breaking one for the company's integrated business model, Mirror Now reported. Laurus said it has operationalised its first commercial-scale peptide plant in Vizag and is expanding capacity for peptide therapeutics, and has agreed to acquire a 60 per cent stake in Canada-based Galenvs Sciences and a 52 per cent stake in SI&C Resins to strengthen its technology platforms.
Source: Mirror Now